A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat
brief summary
A phase 2b, randomized, placebo-controlled study with long-term re-treatment to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat
detailed description
A total of approximately 250 adult participants with Grade 3 or Grade 4 abdominal fat, as assessed by Clinician Reported-Abdominal Fat Rating Scale (CR-AFRS) and Patient Reported-Abdominal Fat Rating Scale (PR-AFRS) at baseline will be enrolled. Each participant will receive up to 4 treatments of allocated study drug administered subcutaneously to the abdomen, once every 3 weeks.
official title
A Phase 2b, Randomized, Placebo-Controlled Study With Long-term Re-Treatment to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat (Stage 1)